678-312-5000

Find A Doctor

  • View All Doctors
ban_img

Cancer Clinical Trials

A clinical trial (also called clinical research) is a research study in which human volunteers to answer specific health questions which can help determine if a medication or a treatment regimen is safe and effective for treating a specific condition or disease. Clinical trials compare the effectiveness of the study medication or treatment against standard, accepted treatment or against a placebo, if no standard treatment exists.

Gwinnett Medical Center offers many opportunities for the community to participate in studies, including:  

Breast Cancer Weight Loss Study (BWEL Study)  This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). Previous studies have found that women who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were thinner when their cancer was diagnosed. This study aims to test whether overweight or obese women who take part in a weight loss program after being diagnosed with breast cancer have a lower rate of cancer recurrence as compared to women who do not take part in the weight loss program. This study will help to show whether weight loss programs should be a part of breast cancer treatment.

Clinical Research Coordinator: Jennifer Williams, 678-312-3831
Clinical Research Nurse: Alex Nash, RN, 678-312-3825

 

POLARIS: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study This Non-Interventional Study will describe and analyze the clinical use of Palbociclib (Ibrance®) in routine clinical practice in the treatment of advanced breast cancer. 

Clinical Research Coordinator: Qun Zeng, 678-312-3829
Clinical Research Nurse: Alex Nash, RN, 678-312-3825

 

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib in Patients with Relapsed, Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell or T-Cell Non-Hodgkin Lymphoma (NHL)  This study will identify the highest dose, and assess the safety, of cerdulatinib (PRT062070) that may be given in patients with relapsed/refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma.

Clinical Research Coordinator: Qun Zeng, 678-312-3829
Clinical Research Nurse: Alex Nash, RN, 678-312-3825

 

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

  • Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)  * Must participate in genetic testing “parent study” in order to be eligible for this treatment trial. This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
  • Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)  * Must participate in genetic testing “parent study” in order to be eligible for this treatment trial. This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
  • Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (ANVIL) This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in different ways and kill tumor cells remaining after surgery and standard of care chemotherapy.

Clinical Research Coordinator: Qun Zeng, 678-312-3829
Clinical Research Nurse: Jennifer Williams, 678-312-3831

 

The ABC Trial This is a randomized phase III trial that investigates how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) breast cancer after chemotherapy, surgery, and/or radiation therapy. Aspirin is a drug that reduces pain, fever, inflammation, and blood clotting. It is also being studied in cancer prevention. Giving aspirin may reduce the rate of cancer recurrence in patients with breast cancer. Participants must be enrolled within one year of diagnosis.  

Clinical Research Coordinator: Qun Zeng, 678-312-3829
Clinical Research Nurse: Alex Nash, RN, 678-312-3825

 

CanStem303C This is a randomized phase 3 trial of napabucasin (an oral drug) plus standard bi-weekly FOLFIRI versus standard bi-weekly FOLFIRI in patients with previously treated metastatic colorectal cancer.

Clinical Research Coordinator: Jennifer Williams, 678-312-3831
Clinical Research Nurse: Alex Nash, RN, 678-312-3825

 

View a list of clinical trials offered by the National Cancer Institute.    

Meet our Investigators 

Principal Investigators are individuals who have primary responsibility for the design, execution and management of a research project and who will be involved in the project in a significant manner.